TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06622278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flipped Classroom
Description: The flipped classroom educational model requires participants to independently review educational material before class, and class time with the health educator is spent engaging in group and individual skills-based activities and problem-solving assignments. The theoretical basis for the development of active learning is to elicit higher cognitive learning, according to the revised Bloom's taxonomy and shift independent student time to passive learning (remembering and understanding) and collaborative student and educator time to active learning (applying, analyzing, evaluating, and creating). Thus, the weight management education will include: case vignettes, group debates/discussions, think-pair-share activities, gamification of health-related topics, creation of meal and physical activity, problem-solving barriers to a healthy diet and physical activity, and hands-on worksheets.
Study: NCT06624631

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delivery strategy A
Description: Delivery of PDMC at the primary admitting facility

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delivery strategy B
Description: Referral to the closest peripheral facility for dispensing of PDMC two weeks post discharge
Study: NCT06625580

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transverse thoracic muscle plane and serratus anterior plane block
Description: ultrasound guided transverse thoracic muscle plane block and serratus anterior plane block will be performed with 0.25% bupivacaine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae plane block
Description: ultrasound guided erector spinae plane block will be performed with 0.25% bupivacaine
Study: NCT05890352

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo optional collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo optional collection of blood

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo optional collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo optional collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT and CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT and CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT and CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo PET/CT and CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT and CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT05607485

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Randomized video numbers
Description: See arm/group description
Study: NCT05890352

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT05189171

Intervention type: DEVICE
Intervention: MicroOrganoSphere (MOS) drug screen
Description: Patient-derived models of cancer, called MOS, will be generated from a biopsy of a subject's adenocarcinoma of the colon and/or rectum that is metastatic to the liver and a drug screen using standard-of-care drugs used will be completed (oxaliplatin, irinotecan, 5-FU/capecitabine (Xeloda), bevacizumab, panitumumab or cetuximab, trifluridine/tipiracil (Lonsurf), regorafenib and pembrolizumab or nivolumab). Subjects will receive standard-of-care therapy for CRC dictated by their treating physicians.
Study: NCT04884490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Description: Tab. Co-trimoxazole 960 mg (trimethoprim 160mg + sulphamethoxazole 800mg) thrice (8 hourly) daily for 7 days orally.
Study: NCT05890352

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT04884490

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo thrice (8 hourly) daily for 7 days orally.
Study: NCT05890352

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tafasitamab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Given IV
Study: NCT06625281

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epleys Maneuver
Description: * The patient begins in an upright sitting posture, with the legs fully extended and the head rotated 45 degrees towards the affected side.~* The patient is then quickly and passively forced down backwards by the therapist performing the treatment into a supine position with the head held approximately in a 30-degree neck extension~* The therapist observes the patient's eyes for primary stage nystagmus. The patient remains in this position for 1-2 minutes.~* The patient's head is then turned 90 degrees to the opposite direction so that the unaffected ear faces the ground, for 1-2 minutes.~* Keeping the head and neck in a fixed position relative to the body, the individual rolls onto their shoulder, rotating the head another 90 degrees in the direction they are facing. The patient is now looking downwards at a 45-degree angle.~* The eyes should be immediately observed by the therapist for secondary stage nystagmus. The patient remains in this position for 1-2 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Semont-plus maneuver
Description: * The Semont-plus maneuver includes the upright position with turning of the head by 45° toward the non-affected side.~* Then movement of the body by 150° toward the affected side, which moves the otoconia further in the direction in which they should move and since the clot is beyond the vertex, the movement of body by 240° moves the clot into the direction of the vestibulum.
Study: NCT06329531

Intervention type: OTHER
Intervention: Screen of Cancer Survivorship - Occupational Therapy Services (SOCS-OTS)
Description: Given by Questionnaire
Study: NCT06625281

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brandt-Daroff exercises
Description: * Patient sits on the edge of bed. and lies down onto the side that causes dizziness to increase. Look towards the ceiling. Stay in this position for 2 minutes.~* Sits upright and then wait for 30 seconds.~* Moves rapidly to the opposite side for 2 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brandt-Daroff exercises
Description: * Patient sits on the edge of bed. and lies down onto the side that causes dizziness to increase. Look towards the ceiling. Stay in this position for 2 minutes.~* Sits upright and then wait for 30 seconds.~* Moves rapidly to the opposite side for 2 minutes.
Study: NCT06625866

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback and information
Description: The healthcare professionals in the intervention arm will be exposed to feedback and information behavioral strategies. Namely, interns, residents, obstetricians/gynecologists, and nurses will receive written feedback about the episiotomy rates in the hospital each month during the study period. Moreover, at least two academic sessions will be designed to outline the indications, surgical technique, complications, and surgical ethics for the procedure (i.e., episiotomy). Likewise, each session will also include a patient testimonial about their experience during delivery and their follow-up when an episiotomy was performed.~The feedback intervention will be provided for 2 months, and the feedback intervention + the information intervention will be provided for 2 additional months.
Study: NCT06624683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intelligent footbath basin
Description: before night sleep, takes 30 mins, starting from the first day of the menstrual cycle (MC) and continuing for 28 days.
Study: NCT06319547

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracocentasis
Description: patients will be submitted to diagnostic pleural fluid study, chest x-ray, liver function and blood picture
Study: NCT04617262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Problem Management Plus
Description: Five sessions of low-intensity, trans-diagnostic psychological intervention including the teaching and practice of the following strategies: stress management, problem solving, behavioral activation, and strengthening social support
Study: NCT06626178

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT) scan low dose
Description: The radiological investigation will be done with multi-detector-row (64 or more) computed tomography (CT) scanners at low-dose protocol. The low-dose spiral CT consists of a CT study of the chest, without the need for injection of contrast medium, characterized by less radio exposure than the standard CT of the chest with high sensitivity in detecting pulmonary nodules.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT) scan low dose
Description: The radiological investigation will be done with multi-detector-row (64 or more) computed tomography (CT) scanners at low-dose protocol. The low-dose spiral CT consists of a CT study of the chest, without the need for injection of contrast medium, characterized by less radio exposure than the standard CT of the chest with high sensitivity in detecting pulmonary nodules.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Peripheral venous blood sampling (20 ml)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Peripheral venous blood sampling (20 ml)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue sampling (lung)
Description: sampling of tumor and healthy tissue during surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spirometry
Description: Spirometry measurement using spirometer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Compilation of epidemiological questionnaire, quality of life questionnaires

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoking cessation program
Description: Study guarantee valid support for quitting smoking, which for a smoker is a more effective intervention to reduce the risk of developing lung cancer, myocardial infarction and other smoking-related diseases

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoking cessation program
Description: Study guarantee valid support for quitting smoking, which for a smoker is a more effective intervention to reduce the risk of developing lung cancer, myocardial infarction and other smoking-related diseases

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbon monoxide measurment
Description: Measurment of Carbon monoxide (CO)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiovascular primary prevention
Description: Intervention done in order to find the presence of coronary calcifications
Study: NCT06624826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emmetropic modality
Description: PureSee IOL, emmetropic modality

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monovision modality
Description: PureSee IOL, monovision modality
Study: NCT06625346

Intervention type: DRUG
Intervention: Fixed-Dose Combination of Amlodipine/Valsartan
Description: Amlodipine and valsartan are two of the most commonly prescribed medications for the treatment of hypertension (high blood pressure). Amlodipine is a calcium channel blocker that works by relaxing the blood vessels, while valsartan is an angiotensin receptor blocker that works by blocking the effects of the hormone angiotensin II, which causes blood vessels to constrict. The combination of amlodipine and valsartan in a single pill has been shown to be more effective in lowering blood pressure than either medication alone. This is because the two medications have different mechanisms of action and work together to provide a more comprehensive approach to blood pressure control.
Study: NCT05244148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IP1 - Stérimar BLOCKED NOSE Baby nasal spray
Description: 1 to 2 sprays per nostril at least 2 twice a day and, as needed, up to a maximum of 6 times a day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IP2 - Stérimar Stop & Protect Cold Baby + standard of care
Description: 1 to 2 sprays per nostril at least 2 twice a day and, as needed, up to a maximum of 6 times a day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: hydration + rest at home + if needed paracetamol

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: hydration + rest at home + if needed paracetamol

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard of Care
Description: hydration + rest at home + if needed paracetamol
Study: NCT06006923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: A multi-kinase inhibitor that targets several receptor tyrosine kinases including vascular endothelial growth factor receptor (VEGFR), which may also have immunomodulatory affect in the tumor microenvironment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: An anti-PD1 blockade / immune checkpoint inhibitor treatment approved for patients with high microsatellite instability (MSI-H) colorectal cancer (CRC) as first line therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: An anti-PD1 blockade / immune checkpoint inhibitor treatment approved for patients with high microsatellite instability (MSI-H) colorectal cancer (CRC) as first line therapy.
Study: NCT06299514

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pace and Ablate
Description: BiVentricular Pacing (BiVP) or Conduction System Pacing(CSP) followed by AtrioVentricular Node Ablation (AVNA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medication
Description: Optimization of heart failure therapies includes maximum tolerated doses of beta-blockers, aldosterone antagonists, ACE inhibitors, ARB, diuretics, ARNis
Study: NCT04925674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC53856
Description: The 100mg dose cohort in the hemodialysis: D1 single oral administration of the investigation product 2.5h before hemodialysis; Three times a week for 6 weeks starting from D8, oral administration of the test drug 2.5h after hemodialysis.~The rest dose cohorts in the hemodialysis: Three times a week for 6 weeks starting from D1, oral administration of the investigation product 2.5h after hemodialysis.~The dose cohort in the peritoneal dialysis: Three times a week for 6 weeks starting from D1, oral administration of the investigation product after fasting.
Study: NCT05890352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Given PO
Study: NCT06457100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol Injection
Description: Before induction of anesthesia, 0.5 mg/kg of esmolol was pumped intravenously and infused within 1 minute, followed by a pumping rate of 3 mg/kg/h until the end of the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine IV
Description: Before induction of anesthesia, 2 mg/kg of lidocaine was pumped intravenously and infused within 10 minute, followed by a pumping rate of 2 mg/kg/h until the end of the procedure.
Study: NCT05890352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Given PO
Study: NCT05971342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gelatin sponge-loaded apoptotic vesicle complex（Kuaikang®)
Description: The experimental group
Study: NCT06202664

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Block
Description: Erector Spinae block under ultrasound guidance will be administered bilaterally at T6 level. The block will be administered after induction of general anesthesia with 1mg of IV Midazolam, 2mg/kg of IV Propofol and 0.5 mg/kg of IV Atracurium. After induction patient will be placed in lateral position and then under ultrasound guidance Erector Spinae Block will be administered at T6 level. Drugs administered in the block will include 30ml of 0.25% Bupivacaine and 10ml of 1% Lignocaine (bilaterally). Skin incision for trocar insertion will be given 15 mins after administration of Erector Spinae Block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid Analgesic
Description: This group of patient will receive general anesthesia induction with 1mcg/kg of IV Fentanyl, 2mg/kg of IV Propofol and 0.5 mg/kg of IV Atracurium. 1g of IV paracetamol and 30 mg of IV Ketorolac will be given if intra-operative course suggest inadequate analgesia (Rise in Heart rate ± Blood Pressure by more than 20% from baseline).
Study: NCT05971342

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gelatin sponge only （Kuaikang®)
Description: The positive control group
Study: NCT06203652

Intervention type: OTHER
Intervention: Real-world regimen
Description: The final personalized management strategy is determined based on current conventional treatment options, physician and patient preferences.The following protocols: chemotherapy, immunochemotherapy,Anti-cd20 monoclonal antibody, BTKi and so on
Study: NCT05307328

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SPI-62
Description: 11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-62
Description: 11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive tablets identical to SPI-62 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inactive tablets identical to SPI-62 tablets
Study: NCT05104801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitravatinib
Description: sitravatinib 100mg QD PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitravatinib
Description: sitravatinib 100mg QD PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab
Description: tislelizumab 200mg Q3W IV
Study: NCT04707703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazonium Injection [Cresemba]
Description: Intravenous isavuconazonium sulfate 372 mg every 8 hours for 6 doses followed by intravenous isavuconazonium sulfate 372 mg once daily for up to 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous placebo every 8 hours for 6 doses followed by intravenous placebo once daily for up to 28 days
Study: NCT04702880

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986012
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT05688098

Intervention type: DRUG
Group type: OTHER
Intervention: Irbesartan/Amlodipine High FDC
Description: Irbesartan/Amlodipine High FDC

Intervention type: DRUG
Group type: OTHER
Intervention: Irbesartan
Description: Co-administration of Irbesartan and Amlodipine High